INCY vs IOVA
Incyte vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | INCY | IOVA |
|---|
| AI Score |
72
|
67
|
| Price |
$121.08
|
$6.49
|
| P/E Ratio |
14.89×
|
-9.27×
|
| ROE |
24.9%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
116.3%
|
| Debt / Equity |
0.01×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
79.2
|
| Beta |
0.769
|
0.701
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus IOVA.
INCY leads by 5 points.
INCY scores 72/100 (Buy) versus IOVA at 67/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical